Welcome to LookChem.com Sign In|Join Free
  • or
tert-Butyl-(6-furan-2-yl-hexyloxy)-diphenyl-silane is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

738604-48-3

Post Buying Request

738604-48-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

738604-48-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 738604-48-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,3,8,6,0 and 4 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 738604-48:
(8*7)+(7*3)+(6*8)+(5*6)+(4*0)+(3*4)+(2*4)+(1*8)=183
183 % 10 = 3
So 738604-48-3 is a valid CAS Registry Number.

738604-48-3Relevant academic research and scientific papers

Furan derivatives, method of synthesis and uses thereof

-

Page/Page column 19, (2008/12/06)

The present invention relates to furan derivatives of formula (I), their method of synthesis and uses thereof. Concretely, the compounds disclosed have proved to be inhibitors of glycogen synthase kinase 3β, GSK-3 β, which is known to be involved in different disease and conditions, such as Alzheimer's disease or non-insulin dependent diabetes mellitus. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a GSK-3 mediated disease or condition.

Cyclopentanone derivatives, method of synthesis and uses thereof

-

Page/Page column 24, (2008/12/06)

The present invention relates to cyclopentanone derivatives of formula (I), their method of synthesis and uses thereof. Concretely, the compounds disclosed have proved to be inhibitors of glycogen synthase kinase 3β, GSK-3 β, which is known to be involved in different disease and conditions, such as Alzheimer's disease or non-insulin dependent diabetes mellitus. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a GSK-3 mediated disease or condition.

The furan approach to oxacycles: Synthesis of medium-size 2,3-disubstituted oxacycles

Pérez, Manuel,Canoa, Pilar,Gómez, Generosa,Terán, Carmen,Fall, Yagamare

, p. 5207 - 5209 (2007/10/03)

We describe an efficient new approach for the synthesis of medium-size oxacycles that is based on the oxidation of a furan ring with singlet oxygen followed by an intramolecular Michael addition. This present study enlarges the scope of the furan approach strategy for the synthesis of oxepanes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 738604-48-3